drugset / Press release
Biosimilar candidate of Fresenius Kabi shows positive results in two clinical trials
2021-09-07 · Fresenius Kabi · original fresenius.com ↗
Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11456, a tocilizumab biosimilar candidate, successfully met the primary and secondary endpoints in two consecutively conducted clinical trials. For more information, please visit the Fresenius Kabi website.
The release as fetched from its publisher. fresenius.com ↗